Answers are grounded in this paper and cite their sources.
Narrative review shows SGLT2 inhibitors improve cognitive function in heart failure patients, suggesting neuroprotective mechanisms that warrant dedicated large-scale clinical trials.
Objective: SGLT2 inhibitors belong to a new category of oral antidiabetic medications that decrease blood glucose by obstructing glucose reabsorption in the proximal tubule (PCT), resulting in elevated urinary levels of sodium and glucose. The 2023 ESC guidelines for acute and chronic heart failure encourage the usage of SGLT2 inhibitors in patients with HFmrEF and HFpEF to lower the danger of hospitalization or cardiovascular mortality in heart failure patients. Cognitive decline is a significant issue for heart failure patients. This narrative review's objective is to examine the impact of SGLT2i on cognitive dysfunction associated with heart failure and foster further research, predominantly in the form of large-scale clinical trials. Design and method: An exhaustive literature search was executed on PubMed to analyze the fundamental mechanisms of SHLT2 inhibitors on cognitive impairment in heart failure patients, related clinical evaluations, the consequences of cardiac dysfunction on cognitive function, and possible underlying mechanisms. Results: The published literature substantiates the argument that cognitive impairment is provoked by cardiac dysfunction. Current research suggests that cognitive dysfunction in patients with heart failure results from inadequate cerebral perfusion, the Locus coeruleus noradrenergic system, chronic inflammation, mitochondrial dysfunction, and microRNA-1. Furthermore, numerous randomized controlled trials have confirmed that SGLT2 inhibitors, with or without diabetes mellitus, enhance cardio-renal outcomes in patients. SGLT2 proteins are present in the central nervous system (CNS). SGLT2 inhibitors reduce oxidative stress, inflammation, and endothelial cell proliferation, as well as improve brain mitochondrial function, synaptic plasticity, acetylcholinesterase activity, amyloid plaques, and modulation of the mTOR pathway. They also attenuate brain injury and cognitive decline. There are additional clinical studies that demonstrate the reduction in the risk of cerebrovascular events and dementia through SGLT2i treatment. Conclusions: To summarize, all existing studies establish the direct and indirect neuroprotective effects of SGLT2i. Nevertheless, there is limited clinical research on using SGLT2i for the treatment of cognitive dysfunction related to heart failure. Further clinical experiments are required to determine the effectiveness of SGLT2i treatment in improving cognitive dysfunction associated with heart failure.
No takes yet. Share an insight, caveat, or question.
Di et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: